These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3144539)

  • 21. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers.
    Pecquet S; Ravoire S; Andremont A
    J Antimicrob Chemother; 1990 Jul; 26(1):125-9. PubMed ID: 2211433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis.
    Pust RA; Ackenheil-Köppe HR; Weidner W; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():227-30. PubMed ID: 3144543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of method, medium, pH and inoculum on the in-vitro antibacterial activities of fleroxacin and norfloxacin.
    Hohl P; Felber AM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():71-80. PubMed ID: 3144552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.
    Hoogkamer JF; Kleinbloesem CH
    Drugs; 1995; 49 Suppl 2():346-8. PubMed ID: 8549357
    [No Abstract]   [Full Text] [Related]  

  • 27. Morphological response of mycoplasma to fleroxacin.
    Werk R; Schneider L
    Infection; 1989; 17(6):405-6. PubMed ID: 2515157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro susceptibility of Campylobacter jejuni and Campylobacter coli to quinolone antibiotics].
    Gür D; Hasçelik G; Akyön Y; Akalin HE; Diker S
    Mikrobiyol Bul; 1989 Jul; 23(3):185-9. PubMed ID: 2518646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The penetration of fleroxacin into intra-abdominal abscesses.
    Youngs DJ; Tudor RG; Yoshioka K; Keighley MR
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():115-8. PubMed ID: 3144528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between growth curves and killing curves of Escherichia coli in the presence of fleroxacin and ampicillin.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1989; 35(6):423-30. PubMed ID: 2515040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil.
    Baba S; Mori Y; Maruo T
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():195-7. PubMed ID: 3144538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penetration of ciprofloxacin and fleroxacin into biliary tract.
    Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
    Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():49-54. PubMed ID: 3144549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of quinolones on the faecal flora.
    Midtvedt T
    Scand J Infect Dis Suppl; 1990; 68():14-8. PubMed ID: 2218416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fleroxacin concentrations in myometrium, ovary and fallopian tube.
    Portmann R; Hansz C; Stiglmayer R; Weidekamm E
    J Antimicrob Chemother; 1989 Apr; 23(4):662-4. PubMed ID: 2501273
    [No Abstract]   [Full Text] [Related]  

  • 40. In-vitro activity of fleroxacin against Chlamydia trachomatis.
    Steele-Mortimer O; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.